At a Glance
Myomo (NYSE:MYO) is currently in the spotlight, thanks to its impressive 2023 stock performance and a ranking of 6th, overall, on Seeking Alpha’s Quant. The company, however, is at a crossroads, especially with the recent change by Centers for Medicare & Medicaid Services’ [CMS] affecting its MyoPro product. This brings a mix of opportunity and uncertainty, particularly around pricing and market reach. Financially, Myomo looks stable on paper with solid liquidity and a healthy balance sheet, but there are concerns about dilution, persistent losses, and rising operational costs. In a market buzzing with competition and innovation, Myomo needs to stay sharp in its product development and market strategies. For investors, it’s a time to be watchful. Myomo’s next moves in handling these challenges and leveraging opportunities will be key to understanding its future prospects in the medical robotics field.
Myomo’s MyoPro: Bracing for Change in Medical Robotics
In the dynamic and innovative landscape of medical robotics, Myomo has emerged as a notable player, particularly with its MyoPro product line. The company’s journey through 2023, especially in the third quarter, is marked by significant developments and challenges that provide a multifaceted view of its current standing and future prospects.
The most noteworthy development for Myomo in recent times has been the CMS reclassification of its MyoPro as a brace, a change that will take effect on January 1, 2024. This reclassification is pivotal for Myomo because it aligns MyoPro’s reimbursement with a lump-sum model, akin to other medical devices. The anticipated effect of this decision is a potentially broader market reach and enhanced accessibility for Medicare beneficiaries. However, the absence of a national fee for MyoPro means that reimbursement rates remain uncertain, impacting Myomo’s pricing strategy and market penetration efforts. The CMS has proposed fee schedule rates for MyoPro’s Healthcare Common Procedure Coding System (HCPCS) codes, L8701 and L8702, at $31,745.42 and $62,457.28, respectively, but these rates are subject to review and finalization. This situation presents a nuanced challenge for Myomo, balancing the promise of expanded market access against the complexities of a fluid reimbursement landscape.
Myomo’s financials for Q3 2023 indicate a period of both progress and challenges. The company recorded a 28% Y/Y revenue increase to $5.08 million, mainly driven by MyoPro unit sales. Despite a 7% drop in the average selling price per unit to about $42,700, reflecting market pricing pressures, gross profit grew from $2.64 million to $3.49 million. The gross margin improved to 68.7%, a testament to cost efficiency and better absorption despite lower prices and increased warranty provisions. However, operating expenses edged up to $5.51 million, a modest 1% increase due to higher incentive compensations, partially offset by a 27% reduction in advertising costs. The net loss improved slightly, down from $2.83 million to $2.03 million. Of concern is the substantial increase in the weighted average number of common shares, from 7.06 million to 35.27 million, raising questions about potential shareholder equity dilution.
Myomo, operating in the competitive orthotics and prosthetics sector, particularly in robotic arm prosthetics, confronts significant challenges from industry peers like Ekso Bionics (EKSO) and ReWalk Robotics (RWLK), alongside major entities such as Mobius Bionics, Fillauer Companies, exiii, Ossur, Vincent Medical, Ottobock, TASKA Prosthetics, Touch Bionics, and Touch Bionics. These rivals each contribute distinct innovations and strengths, escalating the competition for Myomo. This landscape demands Myomo to prioritize not just product innovation but also strategic positioning in the market. In this dynamic environment, navigating operational hurdles like supply chain efficiency, impactful marketing, and financial robustness is crucial. Myomo’s strategy to expand its Medicare Part B patient base and enhance market reach underscores its adaptability. However, it must traverse a densely competitive field where fostering innovation, forging strategic alliances, and optimizing operations are vital for sustaining its market position. Additionally, the substantial out-of-pocket costs for patients, despite CMS reclassification, pose a significant obstacle. Even with 80% Medicare coverage, patients still face considerable expenses for the MyoPro device.
In conclusion, Myomo journey through the latter part of 2023 presents a complex but hopeful narrative. The CMS reclassification of MyoPro opens up new opportunities for revenue growth and market expansion. However, the company must adeptly manage the intricacies of the reimbursement landscape, intensifying market competition, and internal operational challenges. Myomo’s success in navigating these multifaceted challenges will be crucial in determining its future in the medical robotics industry and its impact on improving the lives of individuals with neuromuscular disorders.
Turning to Myomo’s balance sheet, the combined value of ‘cash and cash equivalents’, ‘marketable securities’, and ‘investments’ stands at approximately $11.1M ($6.9M in cash and equivalents and $4.2M in short-term investments), boosted by an August public offering of $4.4 million. The current assets totaling $16M against current liabilities of $5.8M results in a current ratio of about 2.8, indicating a comfortable level of short-term financial health. The total liabilities of $6M are significantly lower than the total assets of $17M, suggesting a solid asset-to-debt ratio.
Over the last nine months, the company’s net cash used in operating activities was about $3.8M, leading to a monthly burn rate of roughly $0.42M. With $11.1M in liquid assets, the cash runway is approximately two years. However, this analysis, based on past data, may not reflect future performance.
Considering the relatively extended cash runway and current asset-to-liability configuration, the odds of Myomo requiring additional financing within the next twelve months appear low-to-medium.
In summary, Myomo’s short-term financial health is robust, supported by a strong current ratio and a solid asset-to-debt standing. In the long term, their financial health also appears adequate, given the extended cash runway and lower likelihood of needing near-term financing.
Myomo’s market capitalization of $137.35M, combined with a high stock momentum (+766.22% over a year vs SPY’s +21.14%), suggests strong market confidence.
Growth prospects appear promising, with analyst projections, per Seeking Alpha, indicating a consistent increase in sales (up to $28.54M by 2025).
The low short interest of 1.60% with 235.83K shares short and a days-to-cover ratio of 0.49 indicates minimal market skepticism.
Institutional ownership stands at 23.10%, with significant activity in new positions (10 holders with 2,254,901 shares) compared to sold out positions (1 holder with 115,522 shares), highlighting institutional interest. Notable institutions include Aigh Capital Management, Worth Venture Partners, and Herr Investment Group. Insider trades show a positive net activity with more buys than sells over the past 12 months (1,445,649 net shares bought), suggesting insider confidence.
Overall, considering these factors, Myomo’s market sentiment can be qualified as “Robust”.
My Analysis & Recommendation
Analyzing Myomo’s situation as 2023 wraps up, it’s clear they’re at a pivotal moment. The recent MyoPro reclassification by CMS is a double-edged sword: it holds promise but brings uncertainty about reimbursement rates, which are crucial for Myomo’s pricing and market reach. Myomo’s strong sales growth and better gross margins are encouraging, yet we can’t ignore the rising operating costs and the issues around diluting shareholder equity.
In the cutthroat orthotics and prosthetics market, where innovation is non-stop, Myomo faces intense competition. To stay ahead, they need to pour significant resources into product development, smart marketing, and winning over customers. However, Myomo’s research and development spending seems modest, under $1 million for the third quarter and just 14% of total revenues. This strategy helps them keep better margins than competitors like Ekso Bionics and ReWalk Robotics, but it does raise questions about their ability to stay ahead in this fast-evolving field.
Looking ahead, investors should watch a few key areas. First, how CMS finalizes its fee schedule will greatly impact Myomo’s finances. We should have more clarity on this by early 2024, shedding light on their revenue potential and profit trajectory. Second, it’s vital to track how well Myomo handles its operational costs, especially with a potential revenue boost on the horizon. Third, how Myomo tackles market penetration and competition will be crucial to watch.
For risk management, diversifying investments might be wise, given Myomo’s current situation. While they seem financially stable now, their long-term success depends on how they handle reimbursement issues and intense market competition.
A cautious “Hold” stance on Myomo seems wise at this point. Their recent stock surge, indicating market trust in their growth potential, is notable. However, the unclear path to profitability and the tough market competition call for a vigilant approach. Investors should keep an eye on Myomo’s strategic moves and financials in the upcoming quarters, especially their progress towards cash flow breakeven and how they handle competition, to reevaluate their stance as new information comes in.
Lastly, investing in microcap companies like Myomo comes with its own set of risks. Their stocks are usually more volatile and less liquid, leading to bigger price fluctuations and potential challenges in buying or selling shares. Microcaps often have limited access to capital, which can restrict their growth and research funding. Also, there’s typically less analyst coverage, which might lead to less informed investment decisions. In short, only invest what you’re prepared to risk losing.